Gold Conjugate Pad Preparation & Conjugation for Lateral Flow Tests

Run interpretation involves two phases: the amplification profile showing CT values (expecting zeros in mutation channels) and the melt plot report showing Tm values. The RNA internal control uses standard PCR detection and should show valid results. Melting peaks in mutation channels indicate presence of specific mutations. Invalid results occur when internal control fails or melting peaks are absent despite positive specimens. Troubleshooting involves retesting with new reaction mix or 1:10 dilution in universal transport medium to address potential inhibitors affecting melting analysis. Internal validation demonstrated 10/10 UK variant specimens showed N501Y, while 9/10 South African/Brazilian specimens showed both N501Y and E484K. The assay can distinguish E484K from E484Q based on their distinct Tm shifts.

This video lesson covers the validation and troubleshooting of immunoassays for complex biological samples, explaining key figures of merit such as precision, accuracy, sensitivity, and selectivity, while addressing unique challenges including matrix effects (interference from biological components like proteins, DNA, and salts that can cause false positives or negatives), nonspecific binding, and cross-reactivity of antibodies; the instructor demonstrates how to troubleshoot common calibration curve problems including high background (often due to poor blocking), low signal (from experimental errors or reagent degradation), and noise (from inconsistent washing or pipetting), emphasizing that recognizing these three classic symptoms enables rapid diagnosis and solution implementation.

This section covers qPCR chemistry selection and assay optimization. Two main chemistries exist: SYBR Green (intercalating dye) offers sensitivity and low cost but requires specificity verification via melt curves and gels; hydrolysis probes (TaqMan) provide high specificity and multiplexing capability (2-5 targets) but higher cost. Assay design requires: 70-200 bp amplicons, 50-60% GC content, intron-spanning primers for gene expression, similar annealing temperatures (~60°C), and avoidance of GC clamps, secondary structures, and primer-dimers. Probe-based assays require probes 5-10°C higher than primers with 30-80% GC content. Validation requires: sequence validation using OligoEvaluator, optimization of primer/probe concentrations and annealing temperature via gradient PCR, standard curve validation (10-fold dilutions in triplicates), and melt curve analysis. Acceptable efficiency is 90-110%. Essential controls include water negative control, positive control, and no-RT control. Reference genes must be validated for stability in specific conditions, with at least two genes recommended. Troubleshooting poor signal involves checking positive control first, then sample quality or assay optimization. Poor reproducibility requires pipette calibration, larger volumes, primer-dimer checks, and potential assay redesign.

In radioligand binding assays, specific binding refers to the tight, high-affinity interaction between a ligand and its target receptor, while non-specific binding occurs at low-affinity sites throughout the reaction mixture; these two types of binding can be separated by adding excess unlabeled (cold) ligand, which displaces the radioactive (hot) ligand from specific sites but not from non-specific sites, allowing researchers to calculate specific binding by subtracting non-specific binding from total binding and construct saturation curves to determine binding affinity through the dissociation constant (Kd), which equals the ligand concentration at which half of the receptors are bound.

Assay optimization addresses common issues: over-fixation causes weak signals requiring extended protease treatment; under-fixation causes poor morphology. Pretreatment optimization adjusts heat-mediated retrieval time and protease duration based on tissue morphology and signal intensity. Controls are essential: negative probes validate no nonspecific binding; positive probes confirm RNA quality. Automated platforms allow similar optimization by adjusting retrieval time and protease duration. Proper sample preparation and control use ensure reliable results.

Nanoparticle labels provide visual indication on nitrocellulose membranes in lateral flow assays. Colloidal gold is the most common label, producing a strong red color suitable for both visual reading and external scanning. Gold nanoparticles come in various sizes and shapes allowing optimization of assay response, and can be functionalized with bioreceptors through physical absorption or covalent binding. Alternative labels include quantum dots, fluorescent particles, S-tags, surface-enhanced Raman spectroscopy tags, and upconversion nanoparticles. These alternatives offer increased sensitivity for quantitative tests but come at higher costs, often require specialized readers/scanners, and involve more complex conjugation processes. The trade-off between sensitivity and simplicity must be carefully considered based on assay requirements.

Reporter particle selection for lateral flow tests involves trade-offs: (1) Visual particles (gold nanoparticles) enable naked-eye interpretation but may have lower sensitivity; (2) Magnetic particles allow concentration without electrical equipment but may cause aggregation; (3) Fluorescent particles (europium) require readers but offer good sensitivity; (4) Phosphor particles (UCPs) provide stable signals over time. The choice depends on field conditions, need for quantification, and available equipment.

Rapid diagnostic test development requires careful selection of bioreceptors and detection labels. Bioreceptors (typically antibodies) must be stable through drying/rehydration cycles, have fast association kinetics, and high binding affinity. Polyclonal antibodies offer cost-effectiveness while monoclonal antibodies provide higher specificity. Detection labels include gold nanoparticles (most common, visible to naked eye), carbon nanoparticles, magnetic nanoparticles, and fluorescent labels. The development process follows four phases: Phase 1 (feasibility study) identifies biomarkers and evaluates component availability; Phase 2 (development) optimizes antibody selection, conjugation conditions, and membrane characteristics; Phase 3 (validation) tests prototypes with clinical samples to calculate sensitivity, specificity, PPV, and NPV; Phase 4 (manufacturing transfer) scales up production and obtains regulatory approval. Validation is typically conducted at reference laboratories like BBLK and national referral hospitals.

Nanoparticles offer significant advantages over organic dyes: brightness can improve by 100-1000 times compared to 10-20% for organic dyes. Types include quantum dots, lipid-based particles, polymer particles, gold clusters, carbon dots, and aggregation-induced emission particles. Lipid droplets (oil droplets stabilized by surfactants) serve as nanoreactors for biosensing. For dopamine detection, push-pull aldehyde molecules inside droplets react with dopamine through imine formation, changing emission color. Recognition units (boronic acid for catechol groups) enable specificity. Point-of-care diagnostics requires detecting biomarkers (like viral RNA for COVID-19) at very low concentrations (below 1 pM) in biological fluids. Conventional fluorescent techniques only detect nanomolar concentrations, requiring PCR amplification. Bright nanoparticles can potentially replace enzymatic amplification methods. Challenges include making small polymeric nanoparticles (5-14 nm), preventing dye self-quenching at high concentrations, and enabling energy transfer for sensing despite particle size exceeding typical FRET distances. Solutions include replacing small counterions with bulky derivatives (tetrafluoroborate instead of perchlorate) to separate fluorophores in space and prevent self-quenching. Nanoparticles with thousands of encapsulated dyes can be 100-fold brighter than quantum dots.

Beyond gold and latex, alternative detection methods offer different trade-offs for lateral flow assays. Enzymatic detection produces colorimetric readouts but requires substrate addition for visualization, adding complexity. Fluorescent detection offers greater sensitivity than colorimetric methods but requires specialized readers since signals cannot be seen by eye. Lightning Link antibody labeling kits enable rapid conjugation of antibodies to diverse labels including enzymes and fluorescent dyes with just 30 seconds hands-on time. Pre-coated particles provide flexible indirect detection options, useful when screening multiple antibodies during assay development. Each detection method balances sensitivity, instrumentation requirements, manufacturing complexity, and end-user convenience. The choice depends on specific application requirements, available infrastructure, and desired analytical performance characteristics.

ISO 13485 is a quality management system standard for medical devices, first published in 1996 and based on ISO 9001:2000. The standard provides comprehensive requirements for design, development, production, installation, and servicing of medical devices. Key benefits include global market access, process improvement, cost reduction, supply chain monitoring, and regulatory compliance. The standard applies to all organizations manufacturing medical devices and those providing related services. The framework includes: (1) Quality Management System Documentation (Clause 4) including policy, objectives, manual, procedures, and records; (2) Management Responsibility (Clause 5) including commitment, customer focus, policy, planning, authority, communication, and management review; (3) Resource Management (Clause 6) including human resources, infrastructure, and work environment; (4) Product Realization (Clause 7) including planning, customer processes, design and development, purchasing, and production control; (5) Monitoring, Measurement, Analysis, and Improvement (Clause 8) including feedback, complaint handling, audits, non-conforming product control, data analysis, and improvement activities.

ISO 13485:2016 is a quality management standard specifically designed for the design and manufacturing of medical devices, building upon ISO 9001:2000 structure but incorporating additional requirements such as environmental control, sterilization processes, and risk analysis focused on patient safety; it applies to manufacturers, suppliers, and the entire supply chain, requiring organizations to demonstrate compliance with regulatory requirements through certification to ensure devices meet safety standards and minimize risks to patients.

ISO 13485:2016 is an international standard that establishes requirements for quality management systems specifically for medical device manufacturers, focusing on the system itself rather than just the product, and requires organizations to document both internal processes and any outsourced activities to ensure compliance with regulatory requirements for market access.

ISO 13485 is an international standard that provides a framework for establishing a quality management system (QMS) specifically designed for medical device manufacturers, developers, and distributors. The standard requires organizations to implement key documents including a quality policy, quality manual, organizational chart, and quality goals, along with documented processes for document control, design and development, risk analysis, verification and validation, competence training, production control, change management, supplier evaluation, and complaints handling. By implementing ISO 13485 early in the product development lifecycle, medical device companies can efficiently comply with regulatory requirements such as EU MDR/IVDR and FDA 21 CFR Part 820, ensuring they have all necessary documentation for market approval while maintaining product quality and safety.

ISO 13485 is an international standard for quality management systems specifically designed for the medical device industry, providing a framework to ensure regulatory compliance across different countries and enabling companies to qualify as suppliers through certification; unlike ISO 9001, it allows exclusion only of design controls (Clause 7.3) while other clauses can be claimed as non-applicable with proper justification, and it requires documentation of 28 procedures and 44 records across its eight clauses organized around a process approach involving seven elements per process.